In search of measures to improve the detection of increased cardiometabolic risk in children using second-generation antipsychotic medications

References

• Kalverdijk LJ, Bachmann CJ, Aagaard L, et al. A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012. Child Adolesc Psychiatry Ment Health. 2017;11:55.
   PubMed Web of Science ®Google Scholar
• Varimo E, Saastamoinen LK, Ratto H, et al. New users of antipsychotics among children and adolescents in 2008-2017: a nationwide register study. Front Psych. 2020;11(316).
   Google Scholar
• Correll CU, Sikich L, Reeves G, et al. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry. 2020;19(1):69–80.
   PubMed Web of Science ®Google Scholar
• Galling B, Roldán A, Nielsen RE, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73(3):247–259.
   PubMed Web of Science ®Google Scholar
• Lee H, Song D, Kwon JW, et al. Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: a population-based nested case-control study. Eur Child Adolesc Psychiatry. 2018;27(10):1321–1334.
   PubMed Web of Science ®Google Scholar
• Nicol GE, Yingling MD, Flavin KS, et al. Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths: a randomized clinical trial. JAMA Psychiatry. 2018;75:788–796.
   PubMed Web of Science ®Google Scholar
• Sjo CP, Stenstrøm AD, Bojesen AB, et al. Development of metabolic syndrome in drug-naive adolescents after 12 months of second-generation antipsychotic treatment. J Child Adolesc Psychopharmacol. 2017;27:884–891.
   PubMed Web of Science ®Google Scholar
• Chen W, Cepoiu-Martin M, Stang A, et al. Antipsychotic prescribing and safety monitoring practices in children and youth: a population-based study in Alberta, Canada. Clin Drug Investig. 2018;38(5):449–455.
   PubMed Web of Science ®Google Scholar
• Hayden JD, Horter L, Parsons TII, et al. Metabolic monitoring rates of youth treated with second-generation antipsychotics in usual care: Results of a large US national commercial health plan. J Child Adolesc Psychopharmacol. 2020;30(2):119–122.
   PubMed Web of Science ®Google Scholar
• Okumura Y, Usami M, Okada T, et al. Glucose and prolactin monitoring in children and adolescents initiating antipsychotic therapy. J Child Adolesc Psychopharmacol. 2018;28(7):454–462.
   PubMed Web of Science ®Google Scholar
• Kakko K, Pihlakoski L, Keskinen P, et al. Current follow-up practices often fail to detect metabolic and neurological adverse reactions in children treated with second-generation antipsychotics. Acta Paediatr. 2020;109(2):342–348.
   PubMed Web of Science ®Google Scholar
• Holt RI. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019;19(10):96.
   PubMed Web of Science ®Google Scholar
• van der Esch CC, Kloosterboer SM, van der Ende J, et al. Risk factors and pattern of weight gain in youths using antipsychotic drugs. Eur Child Adolesc Psychiatry. 2021;30(8):1263–1271.
   PubMed Web of Science ®Google Scholar
• Nicol G, Worsham E, Haire-Joshu D, et al. Getting to more effective weight management in antipsychotic-treated youth: a survey of barriers and preferences. Child Obes. 2016;12(1):70–76.
   PubMed Web of Science ®Google Scholar
• Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067–1075.
   PubMed Web of Science ®Google Scholar
• Ilies D, Huet A, Lacourse E, et al. Long-term metabolic effects in French-Canadian children and adolescents treated with second-generation antipsychotics in monotherapy or polytherapy: a 24-month descriptive retrospective study. Can J Psychiatry. 2017;62(12):827–836.
   PubMed Web of Science ®Google Scholar
• Arellano-Ruiz P, Garcia-Hermoso A, Cavero-Redondo I, et al. Homeostasis model assessment cut-off points related to metabolic syndrome in children and adolescents: a systematic review and meta-analysis. Eur J Pediatr. 2019;178(12):1813–1822.
   PubMed Web of Science ®Google Scholar
• Shashaj B, Luciano R, Contoli B, et al. Reference ranges of HOMA-IR in normal-weight and obese young caucasians. Acta Diabetol. 2016;53(2):251–260.
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–1495.
   PubMed Web of Science ®Google Scholar
• Tagi VM, Giannini C, Chiarelli F. Insulin resistance in children. Front Endocrinol. 2019;10(342).
   PubMedGoogle Scholar
• Nur Zati Iwani AK, Jalaludin MY, Wan Mohd Zin RM, et al. TG : HDL-C ratio is a good marker to identify children affected by obesity with increased cardiometabolic risk and insulin resistance. Int J Endocrinol. 2019;2019:8586167.
   PubMed Web of Science ®Google Scholar
• Manco M, Grugni G, Di Pietro M, et al. Triglycerides-to-HDL cholesterol ratio as screening tool for impaired glucose tolerance in obese children and adolescents. Acta Diabetol. 2016;53(3):493–498.
   PubMed Web of Science ®Google Scholar
• Di Bonito P, Valerio G, Grugni G, et al. Comparison of non-HDL-cholesterol versus triglycerides-to-HDL-cholesterol ratio in relation to cardiometabolic risk factors and preclinical organ damage in overweight/obese children: the CARITALY study. Nutr Metab Cardiovasc Dis. 2015;25(5):489–494.
   PubMed Web of Science ®Google Scholar
• Panagiotopoulos C, Davidson J, Raghuram K. A Physician handbook for metabolic monitoring for youth with mental illness treated with second-generation antipsychotics. BC Mental Health & Addiction Services; 2010; [cited 2021 Apr 6]. Available from: http://www.bcchildrens.ca/mental-health-services-site/Documents/physicianhandbookformetabolicmonitoring.pdf
   Google Scholar
• Saari A, Sankilampi U, Hannila M, et al. New Finnish growth references for children and adolescents aged 0 to 20 years: length/height-for-age, weight-for-length/height, and body mass index-for-age . Ann Med. 2011;43(3):235–248.
   PubMed Web of Science ®Google Scholar
• Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140:e20171904.
   PubMed Web of Science ®Google Scholar
• Cook S, Weitzman M, Auinger P, et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third national health and nutrition examination survey, 1988. Arch Pediatr Adolesc Med. 2003;157(8):821–827.
   PubMedGoogle Scholar
• Owens S, Galloway R. Childhood obesity and the metabolic syndrome. Curr Atheroscler Rep. 2014;16(9):436.
   PubMed Web of Science ®Google Scholar
• Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice Guideline. J Clin Endocrinol Metab. 2017;102(3):709–757.
   PubMed Web of Science ®Google Scholar
• Peplies J, Jimenez-Pavon D, Savva SC, et al. Percentiles of fasting serum insulin, glucose, HbA1c and HOMA-IR in pre-pubertal normal weight European children from the IDEFICS cohort. Int J Obes. 2014;38(S2):S39–S47.
   Google Scholar
• Melamed OC, LaChance LR, O'Neill BG, et al. Interventions to improve metabolic risk screening among children and adolescents on antipsychotic medication: a systematic review. J Child Adolesc Psychopharmacol. 2021;31(1):63–72.
   PubMed Web of Science ®Google Scholar
• Nyboe L, Lemcke S, Moller AV, et al. Non-pharmacological interventions for preventing weight gain in patients with first episode schizophrenia or bipolar disorder: a systematic review. Psychiatry Res. 2019;281:112556.
   PubMed Web of Science ®Google Scholar
• Pozzi M, Ferrentino RI, Scrinzi G, et al. Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression. Eur Child Adolesc Psychiatry. 2020.
   PubMed Web of Science ®Google Scholar
• Behiry EG, El Nady NM, AbdEl Haie OM, et al. Evaluation of TG-HDL ratio instead of HOMA ratio as insulin resistance marker in overweight and children with obesity. EMIDDT. 2019;19(5):676–682.
   Google Scholar